Do analysts prefer QNRX or RYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SCYX or QNRX?

SCYNEXIS presently has a consensus target price of $33.00, suggesting a potential upside of 566.67%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities research analysts clearly believe SCYNEXIS is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to SCYX or QNRX?

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than SCYNEXIS. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 5 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.50 beat Quoin Pharmaceuticals' score of 0.19 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CLNN or QNRX?

Clene presently has a consensus target price of $34.00, indicating a potential upside of 873.38%. Given Clene's stronger consensus rating and higher possible upside, equities analysts plainly believe Clene is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer CLNN or QNRX?

In the previous week, Quoin Pharmaceuticals had 5 more articles in the media than Clene. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.19 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer QNRX or AGFY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend QNRX or GRCE?

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 162.01%. Given Grace Therapeutics' higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, QNRX or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is QNRX or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.57% -221.17% Grace Therapeutics N/A -36.11% -34.39%

Quoin Pharmaceuticals (QNRX) Competitors

$6.82 +0.04 (+0.52%)

As of 12:31 PM Eastern

Compare

QNRX vs. RYM, SCYX, CLNN, AGFY, and GRCE

Should you buy Quoin Pharmaceuticals stock or one of its competitors? Quoin Pharmaceuticals's main competitors and comparable companies include RYTHM (RYM), SCYNEXIS (SCYX), Clene (CLNN), Agrify (AGFY), and Grace Therapeutics (GRCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Quoin Pharmaceuticals compare to RYTHM?

Quoin Pharmaceuticals (NASDAQ:QNRX) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Quoin Pharmaceuticals had 6 more articles in the media than RYTHM. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 1 mentions for RYTHM. RYTHM's average media sentiment score of 1.87 beat Quoin Pharmaceuticals' score of 0.19 indicating that RYTHM is being referred to more favorably in the news media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
RYTHM	Very Positive

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of RYTHM shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quoin Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%
RYTHM	-6.20%	-12.57%	-2.60%

Quoin Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the broader market.

Quoin Pharmaceuticals has higher earnings, but lower revenue than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A
RYTHM	$17.28M	2.73	-$33.26M	-$10.53	N/A

Summary

Quoin Pharmaceuticals beats RYTHM on 8 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Quoin Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

SCYNEXIS presently has a consensus target price of $33.00, suggesting a potential upside of 566.67%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities research analysts clearly believe SCYNEXIS is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than SCYNEXIS. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 5 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.50 beat Quoin Pharmaceuticals' score of 0.19 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SCYNEXIS has higher revenue and earnings than Quoin Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.39	-$8.61M	-$2.09	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

Summary

SCYNEXIS beats Quoin Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Clene?

Clene (NASDAQ:CLNN) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Clene has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

23.3% of Clene shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Quoin Pharmaceuticals has lower revenue, but higher earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	224.43	-$26.17M	-$3.50	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

Clene presently has a consensus target price of $34.00, indicating a potential upside of 873.38%. Given Clene's stronger consensus rating and higher possible upside, equities analysts plainly believe Clene is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quoin Pharmaceuticals had 5 more articles in the media than Clene. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.19 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Clene beats Quoin Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Agrify?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%
Agrify	-424.11%	-185.90%	-72.67%

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 11.2% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Quoin Pharmaceuticals had 7 more articles in the media than Agrify. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 0 mentions for Agrify. Quoin Pharmaceuticals' average media sentiment score of 0.19 beat Agrify's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
Agrify	Neutral

Quoin Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, indicating that its share price is 896% more volatile than the broader market.

Quoin Pharmaceuticals has higher earnings, but lower revenue than Agrify. Agrify is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A
Agrify	$12.26M	3.54	-$41.75M	-$22.65	N/A

Summary

Quoin Pharmaceuticals beats Agrify on 9 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Grace Therapeutics?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Quoin Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 162.01%. Given Grace Therapeutics' higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -36.11% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%
Grace Therapeutics	N/A	-36.11%	-34.39%

In the previous week, Quoin Pharmaceuticals had 6 more articles in the media than Grace Therapeutics. MarketBeat recorded 7 mentions for Quoin Pharmaceuticals and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Quoin Pharmaceuticals' score of 0.19 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
Grace Therapeutics	Very Positive

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Grace Therapeutics beats Quoin Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.72M	$12.56B	$7.21B	$12.75B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.27	797.28	274.47	25.48
Price / Sales	N/A	755.72	637.09	88.51
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.44	10.45	10.38	6.26
Net Income	-$15.81M	$2.84B	$3.49B	$358.19M
7 Day Performance	-5.99%	-3.32%	-2.11%	-1.31%
1 Month Performance	34.09%	0.98%	0.52%	-2.59%
1 Year Performance	-10.19%	4.05%	24.69%	8.65%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	1.5691 of 5 stars	$6.83 +0.5%	N/A	-10.6%	$13.72M	N/A	N/A	4	Short Interest Increase
RYM RYTHM	0.8973 of 5 stars	$23.71 -0.5%	N/A	N/A	$51.65M	$51.01M	N/A	140	Positive News High Trading Volume
SCYX SCYNEXIS	3.1487 of 5 stars	$4.91 -4.7%	$33.00 +572.1%	-46.0%	$48.85M	$20.60M	N/A	60
CLNN Clene	2.0702 of 5 stars	$3.72 +2.8%	$33.25 +793.8%	-38.4%	$47.80M	$197K	N/A	100
AGFY Agrify	N/A	$23.83 -9.2%	N/A	-49.4%	$47.73M	$12.26M	N/A	140	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. RYM, SCYX, CLNN, AGFY, and GRCE

How does Quoin Pharmaceuticals compare to RYTHM?

Summary

How does Quoin Pharmaceuticals compare to SCYNEXIS?

Summary

How does Quoin Pharmaceuticals compare to Clene?

Summary

How does Quoin Pharmaceuticals compare to Agrify?

Summary

How does Quoin Pharmaceuticals compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. RYM, SCYX, CLNN, AGFY, and GRCE

How does Quoin Pharmaceuticals compare to RYTHM?

Does the media prefer QNRX or RYM?

Do institutionals & insiders believe in QNRX or RYM?

Do analysts prefer QNRX or RYM?

Is QNRX or RYM more profitable?

Which has more volatility & risk, QNRX or RYM?

Which has stronger valuation and earnings, QNRX or RYM?

Summary

How does Quoin Pharmaceuticals compare to SCYNEXIS?

Is SCYX or QNRX more profitable?

Do analysts prefer SCYX or QNRX?

Which has more risk and volatility, SCYX or QNRX?

Does the media refer more to SCYX or QNRX?

Do institutionals & insiders hold more shares of SCYX or QNRX?

Which has preferable earnings and valuation, SCYX or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Clene?

Which has more risk & volatility, CLNN or QNRX?

Do insiders and institutionals believe in CLNN or QNRX?

Is CLNN or QNRX more profitable?

Which has preferable valuation & earnings, CLNN or QNRX?

Do analysts prefer CLNN or QNRX?

Does the media prefer CLNN or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Agrify?

Is QNRX or AGFY more profitable?

Do insiders and institutionals hold more shares of QNRX or AGFY?

Do analysts prefer QNRX or AGFY?

Does the media refer more to QNRX or AGFY?

Which has more volatility and risk, QNRX or AGFY?

Which has preferable valuation and earnings, QNRX or AGFY?

Summary

How does Quoin Pharmaceuticals compare to Grace Therapeutics?

Which has preferable valuation & earnings, QNRX or GRCE?

Which has more volatility and risk, QNRX or GRCE?

Do analysts recommend QNRX or GRCE?

Is QNRX or GRCE more profitable?

Does the media refer more to QNRX or GRCE?

Do institutionals & insiders hold more shares of QNRX or GRCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools